Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

Abstract: Familial hypercholesterolemia (FH) is an autosomal dominant condition with a population prevalence of one in 300–500 (heterozygous) that is characterized by high levels of low-density lipoprotein (LDL) cholesterol, tendon xanthomata, and premature atherosclerosis and coronary heart disease (CHD). FH is caused mainly by mutations in the LDLR gene. However, mutations in other genes including APOB and PCSK9, can give rise to a similar phenotype. Homozygous FH with an estimated prevalence of one in a million is associated with severe hypercholesterolemia with accelerated atherosclerotic CHD in childhood and without treatment, death usually occurs before the age of 30 years. Current approaches for the treatment of homozygous FH include statin-based lipid-lowering therapies and LDL apheresis. Mipomersen is a second-generation antisense oligonucleotide (ASO) targeted to human apolipoprotein B (apoB)-100. This review provides an overview of the pathophysiology and current treatment options for familial hypercholesterolemia and describes novel therapeutic strategies focusing on mipomersen, an antisense apoB synthesis inhibitor. Mipomersen is distributed mainly to the liver where it silences apoB mRNA, thereby reducing hepatic apoB-100 and giving rise to reductions in plasma total cholesterol, LDL-cholesterol, and apoB concentrations in a dose- and time-dependent manner. Mipomersen has been shown to decrease apoB, LDL-cholesterol and lipoprotein(a) in patients with heterozygous and homozygous FH on maximally tolerated lipid-lowering therapy. The short-term efficacy and safety of mipomersen has been established, however, injection site reactions are common and concern exists regarding the long-term potential for hepatic steatosis with this ASO. In summary, mipomersen given alone or in combination with standard lipid-lowering medications shows promise as an adjunct therapy in patients with homozygous or refractory heterozygous FH at high risk of atherosclerotic CHD, who are not at target or are intolerant of statins.

Keywords: antisense oligonucleotide, apolipoprotein B, familial hypercholesterolemia, LDL-cholesterol, metabolism, mipomersen

Introduction

Familial hypercholesterolemia (FH) is the most common and severe form of monogenic hypercholesterolemia. FH was the first genetic disease of lipid metabolism to be clinically and molecularly characterized. The main biochemical abnormality observed in FH is high levels of low-density lipoprotein (LDL)-cholesterol in plasma, due to reduced function of the LDL-receptor pathway, which removes LDL particles from the circulation into the liver. If untreated, patients develop premature coronary heart disease (CHD). The mean age of CHD is between 40 and 45 years in male and a decade later in female FH patients. Most people with FH are undiagnosed or only diagnosed after their first coronary event.
In the late 1930s, Müller was first to recognize that FH was an inherited disorder with related individuals exhibiting xanthomata, hypercholesterolemia, and premature CHD. In the 1960s, Khachadurian showed a gene–dosage effect, with homozygotes having a more severe phenotype than heterozygotes. A breakthrough occurred in the mid-1970s, when Brown et al elucidated the LDL-receptor pathway; Goldstein and Brown showed that defects in the LDL-receptor cause FH, a discovery that earned the authors the Nobel Prize in Physiology or Medicine in 1985.

**Metabolic and molecular basis of FH**

In the late 1970s, in vivo metabolic studies using radiolabeling showed in agreement with the underlying LDL receptor defect that patients with FH are characterized by a decreased clearance of LDL from the circulation and an increase in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect. These findings were confirmed by subsequent stable isotope studies demonstrating that the fractional catabolic rate of LDL–apoB (and, to a lesser extent, very low-density lipoprotein [VLDL]–apoB and intermediate density lipoprotein [IDL]–apoB) is decreased in FH, with the majority of studies also showing increased production of VLDL–, IDL–, and LDL–apoB, with the increased VLDL–apoB production rate being more pronounced in FH homozygotes than in heterozygotes.

FH is an autosomal codominant inherited disorder of lipoprotein metabolism caused mainly by mutations in the LDL-receptor (LDLR) gene. More than 1000 mutations causing FH have been reported; these span the entire LDLR gene, which encodes the LDL-receptor (860 amino acids), and range from single nucleotide substitutions through to large structural rearrangements. While the majority of FH is caused by mutations in the LDLR, amino acid changes in apoB-100 also lead to a form of FH called familial ligand-defective apoB-100. As well as having an important structural role in LDL, apoB-100 acts as a ligand for the LDL-receptor to facilitate clearance of LDL particles from plasma. Rare heterozygous gain-of-function mutations in PCSK9 cause a severe form of FH by causing accelerated degradation of the LDL-receptor, while mutations in the adaptor protein LDLRAP1 can lead to a very rare form of autosomal recessive hypercholesterolemia.

**Prevalence of FH**

Heterozygous FH is estimated to affect 1 in 300–500 individuals worldwide, but is more prevalent in certain populations, where founder effects have led to one in 100 Afrikaners, one in 170 Christian Lebanese, and one in 270 Québécois carrying an FH-causing mutation. Homozygous or compound heterozygous FH has an estimated population prevalence of one in a million, with one in 30,000 Afrikaners, one in 100,000 Christian Lebanese, and one in 275,000 Québécois. The epidemiology, Neolithic origins, and modern distribution of FH has been the subject of a recent review.

**Biochemical and clinical features of FH**

Untreated heterozygous FH patients typically have plasma LDL-cholesterol concentrations ranging from 5–12 mmol/L. The hallmark physical finding in adult patients with FH is the presence of tendon xanthomas, characteristically seen in the extensor tendons of the hands and the Achilles tendons (Figure 1). Less common are xanthomas in the olecranon process and the tibial tuberosity. Corneal arcus and palpebral xanthomas may also be seen, but are less specific features of FH. About half of men and one third of women with FH experience a coronary event by the age of 60 years. Early atherosclerosis (observed as endothelial dysfunction and increased carotid intima-media thickness) can be seen in untreated FH children. The cumulative exposure in cholesterol–life years and the corresponding risk of developing CHD in FH is shown in Figure 2.

Homozygous FH, a more severe form of the disorder, is associated with severe hypercholesterolemia (typically plasma LDL-cholesterol ranging from 15–24 mmol/L) with
widespread accelerated atherosclerotic CHD as early as childhood and without treatment, death usually occurs before age 30. Patients with homozygous FH also exhibit aortic stenosis and atherosclerotic plaques involving the aortic root and supravalvular regions.

Diagnosis criteria for FH

The clinical diagnosis of FH is based on a personal and family history, physical examination findings, and plasma cholesterol concentrations. However, there are no internationally agreed criteria for the phenotypic diagnosis of FH. Three diagnostic criteria currently in use are the Dutch Lipid Clinic Network criteria, the Simon Broome Register Group criteria, and the Make Early Diagnosis – Prevent Early Death (MED-PED) criteria.

Screening for FH

FH meets the World Health Organization criteria for systematic screening. A variety of strategies have been proposed to screen for FH. These include: (1) universal population screening; (2) opportunistic screening of patients consulting for unrelated reasons in primary care; (3) opportunistic screening of patients admitted to hospital with premature CHD; or (4) systematic screening of first-degree relatives of people diagnosed with FH. We have recently shown that the community laboratory has the potential to assist with opportunistic FH screening.

Current approaches for the treatment of homozygous FH

The cornerstone of treatment for FH is diet and lifestyle modifications and pharmacotherapy. 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) are by far the most common and effective drugs with which to treat FH. However, statins require some residual LDL receptor function, thus they are not effective in receptor-negative homozygous FH. Statins decrease atherosclerotic CHD and have been shown to be cost-effective in the treatment of FH. Higher risk patients who require greater LDL-cholesterol and apoB reductions will require combination therapy to achieve therapeutic targets; especially ezetimibe, but also niacin, fibrates, and bile acid-binding resins. Therapeutic efficacy, safety, medication adherence, and compliance should be monitored closely. Effective lipid-lowering therapy has been demonstrated to reduce both mortality and major adverse cardiovascular events in individuals with homozygous FH.

However, trials confirming additional mortality and morbidity benefits over and above that of LDL-cholesterol lowering are required. Ezetimibe has been shown to effectively lower LDL-cholesterol when added to a statin, however, this did not lead to an improvement in carotid intima-media thickness over a 2-year follow-up period.

LDL apheresis is a radical form of treatment for FH that entails the extracorporeal removal of apoB-containing lipoproteins from the circulation. LDL apheresis is indicated for patients with homozygous or compound heterozygous FH, as well as for patients with heterozygous FH with documented CHD who are refractory to pharmacotherapy. Importantly, LDL apheresis improves CHD outcomes, progression of atherosclerosis and aortic fibrosis, endothelial function, and coagulation and is supported by international guidelines. Homozygous patients who are not suitable for LDL apheresis should be considered for liver transplantation or enrolment in clinical trials of novel cholesterol-lowering treatments. It is difficult, if not impossible, to treat a patient with FH to the currently recommended LDL-cholesterol targets. Therefore, it is imperative that new therapeutic strategies be developed to lower LDL-cholesterol.
Novel strategies for the treatment of homozygous FH

Several new therapeutic strategies to lower LDL-cholesterol have been developed for patients with homozygous FH. These include inhibitors of PCSK9, microsomal triglyceride transfer protein (MTTP), and cholesteryl ester transfer protein (CETP), as well as mipomersen, the focus of this review.

PCSK9 inhibitors

PCSK9, a serine protease that binds to the LDL-receptor promoting its degradation, is an important regulator of LDL metabolism. PCSK9 gain-of-function mutations are rare and cause FH, whereas more common loss-of-function mutations cause low LDL-cholesterol and atheroprotection. A compound heterozygote and a homozygote for PCSK9 nonsense mutations each had a very low LDL-cholesterol at ∼0.4 mmol/L. Statins are known to upregulate PCSK9 potentially limiting their efficacy in reducing LDL-cholesterol levels. PCSK9 inhibitors, including antibodies, short-interfering RNA and antisense oligonucleotides are in development as a strategy for lowering plasma LDL-cholesterol and enhancing the LDL-cholesterol-lowering ability of statins. However, PCSK9 inhibitors require some residual LDL-receptor function, thus this approach is limited to heterozygous FH and those homozygotes with reduced, but not absent LDL-receptor function.

MTTP inhibitors

MTTP is a chaperone that facilitates apoB-containing lipoprotein assembly and secretion. MTTP plays a critical role in incorporating hepatic triglyceride with apoB leading to the formation of VLDL, which is subsequently the vehicle of lipid export from the liver. Abetalipoproteinemia is an extreme form of MTTP deficiency characterized by marked hypcholesterolemia, absence of LDL-cholesterol and apoB, and low triglyceride concentrations. In addition, increased transaminases due to hepatic steatosis, acanthocytosis and fat-soluble vitamin deficiency are found. MTTP is a molecular target for therapies to decrease LDL-cholesterol, and apoB and MTTP inhibitors have potential as lipid-regulating and antiatherosclerotic agents.

Lomitapide is a small-molecule MTTP inhibitor designed as an oral, once-daily treatment for homozygous FH. Lomitapide has been granted orphan drug status by the US Food and Drug Administration (FDA), and, in March 2012, Aegerion Pharmaceuticals (Cambridge, MA) filed a New Drug Application (NDA) with the FDA and a Marketing Authorization Application with the European Medicines Agency (EMA) for lomitapide. A long-term safety and efficacy study for lomitapide in homozygous FH showed that the 23 patients who completed the 78-week trial achieved a 38% reduction in LDL-cholesterol, and about half of apheresis patients either reduced or eliminated apheresis therapy. However, therapies for MTTP inhibition have also increased plasma transaminases and caused hepatic steatosis, the long-term significance of which is unknown.

CETP inhibitors

CETP transfers cholesteryl esters from high-density lipoprotein (HDL) to the apoB-containing lipoproteins. Individuals with CETP deficiency due to mutations in CETP have high levels of HDL-cholesterol. Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis. CETP inhibition could potentially correct abnormalities in HDL-functionality in homozygous FH.

Torcetrapib, the first CETP inhibitor to be studied in a Phase III trial, was discontinued due to a number of off-target side effects, namely elevations in systolic blood pressure and increases in plasma aldosterone, sodium, and bicarbonate, and reductions in potassium, leading to increased mortality. Dalcetrapib, a structurally unrelated CETP “modulator,” did not show major side effects; however, a lack of clinically meaningful benefit has meant that further testing of the drug has been halted. Anacetrapib added to statin therapy has been demonstrated to reduce LDL-cholesterol by a further ∼40% and increase HDL-cholesterol by ∼140%. The onus is now on anacetrapib to show that CETP inhibition can prevent coronary events, which is currently being investigated in the REVEAL trial.

Mipomersen

Mipomersen (Kynamro™ [mipomersen sodium]; ISIS Pharmaceuticals, Carlsbad, CA), developed under the name ISIS 301012, is a second-generation antisense oligonucleotide (ASO), which is administered by subcutaneous injection in a formulation with 0.9% sodium chloride and targets apoB-100 mRNA in the liver. Mipomersen has been granted orphan drug status by the FDA for the treatment of homozygous FH. In May 2012, an NDA for mipomersen was filed with the FDA by Genzyme Corporation (Cambridge, MA), who had previously filed mipomersen for marketing approval as a
treatment for homozygous and severe heterozygous FH with the EMA in July 2011.

Mode of action
Mipomersen consists of a 20-mer 2′-O-methoxymethyl modified nucleotide complementary and specific to human apoB-100 mRNA. It distributes mainly to the liver, where it forms a duplex with the target mRNA, causing the mRNA to be cleaved by RNase H and therefore unable to be translated to apoB-100. Hepatic apoB mRNA silencing gives rise to reductions in hepatic apoB and plasma total cholesterol, LDL-cholesterol, and apoB concentrations in a dose- and time-dependent manner. The estimated median effective concentration (EC50) in human liver is 81 ± 122 µg/g.

Pharmacokinetics
Pharmacokinetic studies have indicated that mipomersen has near complete systemic absorption and is rapidly and extensively distributed to tissues (volume of distribution in humans 48.3 L/kg). Animal studies show that the highest levels of the oligonucleotide are found in liver and kidney. In plasma, greater than 85% of mipomersen is bound to plasma proteins. Animal studies suggest that plasma and liver concentrations of mipomersen are in equilibrium with a ratio of 1:6000.

The half-life of mipomersen in humans has been calculated as approximately 30 days. Urinary excretion of the drug is minimal in the first 24 hours. Oligonucleotide metabolites, consisting of between seven and 14 nucleotides of the parent compound, can be detected in urine along with mipomersen. No potential pharmacokinetic interactions of mipomersen occur with coadministration of either simvastatin or ezetimibe, and nor does mipomersen inhibit cytochrome P450 enzyme activities.

Clinical efficacy
Phase I trials showed that, in healthy individuals with mild dyslipidemia, mipomersen produces rapid and dose-dependent prolonged reductions in serum apoB, total cholesterol and LDL-cholesterol, with the apoB and LDL-cholesterol concentrations remaining below baseline for up to 3 months after the last dose.

Subsequent Phase II and III trials have demonstrated that mipomersen is an effective lipid-lowering therapy in FH (Table 1). A Phase II trial in 44 heterozygous FH patients already taking conventional lipid-lowering therapy demonstrated that 300 mg doses of mipomersen could safely, further reduce plasma apoB and LDL-cholesterol concentrations by one-third. Patients were randomized to receive subcutaneous mipomersen (50, 100, 200 or 300 mg) or placebo on days 1, 4, 8 and 11, followed by once-weekly injections to a total of 6 weeks. Significant reductions in apoB (23% and 33%) and LDL-cholesterol (21% and 34%) were observed in the 200 mg and 300 mg dose groups. While there was a trend towards reductions in lipoprotein(a) (Lp(a)), an important risk factor for coronary artery disease in FH that is highly heritable, these changes were not significant. Triglycerides and HDL-cholesterol levels were not significantly affected by mipomersen treatment. Four patients in the 300 mg group continued out to 13 weeks in an extension study, showing reduced apoB and LDL-cholesterol, each by

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient population</th>
<th>Duration</th>
<th>Mipomersen dose (mg/week)</th>
<th>Baseline LDL-C (mmol/L)</th>
<th>% change from baseline ApoB</th>
<th>LDL-C</th>
<th>TG</th>
<th>HDL-C</th>
<th>Lp(a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akdim et al61</td>
<td>Heterozygous FH, n = 44</td>
<td>6 weeks</td>
<td>0</td>
<td>4.42 ± 1.2</td>
<td>−1</td>
<td>0</td>
<td>−16</td>
<td>8</td>
<td>−3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50</td>
<td>5.35 ± 2.0</td>
<td>−10</td>
<td>−13</td>
<td>6</td>
<td>−1</td>
<td>−3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td>4.50 ± 1.0</td>
<td>−8</td>
<td>−11</td>
<td>6</td>
<td>−3</td>
<td>−15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td>4.24 ± 0.8</td>
<td>−23*</td>
<td>−21*</td>
<td>−23</td>
<td>−1</td>
<td>−17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td>4.50 ± 0.9</td>
<td>−33*</td>
<td>−34*</td>
<td>−22</td>
<td>6</td>
<td>−24</td>
</tr>
<tr>
<td>Raal et al65</td>
<td>Homozygous FH, n = 51</td>
<td>26 weeks</td>
<td>0</td>
<td>10.4 ± 3.7</td>
<td>−2.5</td>
<td>−3.3</td>
<td>0</td>
<td>3.9</td>
<td>−7.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td>11.4 ± 3.6</td>
<td>−27*</td>
<td>−25*</td>
<td>−17</td>
<td>15*</td>
<td>−31*</td>
</tr>
<tr>
<td>Visser et al66</td>
<td>Statin-intolerant patients, including FH, n = 33</td>
<td>26 weeks</td>
<td>0</td>
<td>6.3 ± 1.7</td>
<td>−4.3</td>
<td>−2.0</td>
<td>5.8</td>
<td>−2.2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td>6.3 ± 2.4</td>
<td>−46*</td>
<td>−47*</td>
<td>−28</td>
<td>8.1</td>
<td>−27*</td>
</tr>
<tr>
<td>Stein et al70</td>
<td>Heterozygous FH, (abstract) n = 124</td>
<td>26 weeks</td>
<td>0</td>
<td>3.70</td>
<td>7</td>
<td>5</td>
<td>0</td>
<td>5.2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td>3.96</td>
<td>−26*</td>
<td>−28*</td>
<td>−14</td>
<td>3.1</td>
<td>−21*</td>
</tr>
<tr>
<td>Tardif et al71</td>
<td>Severe heterozygous FH, (abstract) n = 58</td>
<td>26 weeks</td>
<td>0</td>
<td>6.44</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td>7.14</td>
<td>−36*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: *P < 0.05.

Abbreviations: ApoB, apolipoprotein B; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); TG, triglyceride.
37% from baseline levels. These parameters remained below baseline for more than 3 months after the last dose.

The efficacy and safety of 200 mg/week mipomersen has also been assessed in homozygous FH. Patients (mean age: 31 years) were all on stable maximum-tolerated lipid-lowering therapy, and over 80% had genetically confirmed homozygous or compound heterozygous FH. Of the 51 patients enrolled, all 17 assigned to the placebo group completed the 26-week treatment period, compared to 28 of the 34 assigned to mipomersen. The reasons given for withdrawal included injection site reactions (n = 2), rash, alanine aminotransferase (ALT) increase, noncompliance, and consent withdrawn. In the mipomersen group, the mean LDL-cholesterol reduced from 11.4 mmol/L at baseline to 8.4 mmol/L (−25%), with reductions near maximum at week 17. However, there was variability in changes to LDL-cholesterol, which ranged between 2% to −82%, and was independent of baseline LDL-cholesterol, age, race, or sex. Significant reductions in Lp(a) (−31%) and triglyceride levels (−17%), and an increase in HDL-cholesterol (15%), were also observed.

Visser et al examined the effect of mipomersen in 33 statin-intolerant patients at high risk for cardiovascular disease. Over half of the patients were FH heterozygotes. Treatment with 200 mg/week mipomersen for 26 weeks resulted in a 47% decrease in LDL-cholesterol, ranging from −19% to −77%. This was predominantly the result of a reduction in small LDL particles (−56%; P = 0.001 vs placebo) rather than large LDL particles (−4%; P < 0.017 vs placebo). While triglycerides and Lp(a) levels were significantly reduced by mipomersen treatment, HDL-cholesterol and apoA-I concentrations did not change.

Safety

The majority of patients treated with mipomersen experience mild, transient injection site reactions, and about one-third experience flu-like symptoms. However, the focus of mipomersen’s safety concerns has been on hepatic steatosis, as this was the major issue with suppression of VLDL production using MTTP inhibitors. Elevated plasma liver transaminases are common in patients on mipomersen therapy, and may be associated with the development of steatosis.

The impact of 200 mg/week mipomersen on intrahepatic triglyceride content, assessed by proton magnetic resonance spectroscopy (1H-MRS), was studied in 21 patients with heterozygous FH. Patients with a baseline liver fat greater than 5% were excluded from the trial. Liver fat content was assessed at baseline, where the mean intrahepatic triglyceride content was 1.2%, and again at weeks 4 and 15. The most common adverse events were injection site reactions, which affected all patients in the mipomersen group (19% of injections) compared to 73% of the placebo group (9% of injections). Flu-like symptoms were observed in 70% of the mipomersen group and 18% of placebo. While no clinically significant increases in ALT were observed, the mean intrahepatic triglyceride content increased 0.8 percentage points in the mipomersen group at week 15, compared to a decrease of 0.1 percentage points in the placebo group (P = 0.051). In one patient, liver fat increased from 0.6% at baseline to 5.7% at week 15, but this appeared to be reversible, decreasing to 2.5% at week 35.

In a Phase III trial of homozygous FH patients, 1H-MRS quantification of liver fat content was performed at baseline and only remeasured in patients with increases in ALT greater than three times the upper reference limit. This corresponded to four patients (12%) in the mipomersen group, and none in the placebo group. While two of these patients did not show an increase in hepatic steatosis, a third showed an increase in hepatic fat content from 9.6% to 24.8%. Mipomersen treatment gave a strong lipid-lowering response in this patient, with a 75% reduction in LDL-cholesterol to <1.8 mmol/L achieved by week 13. The fourth patient had increased liver transaminases at baseline and again at week 17 where the protocol-defined stopping rule was met and dosing stopped.

In a trial of 33 statin-intolerant patients, the majority with FH, 81% of mipomersen-treated patients had increases in ALT above the upper limit of normal, compared to 25% of the placebo group. One-third of mipomersen-treated patients showed persistent elevations in liver transaminases greater than three times the upper reference limit. One patient in the mipomersen group met a stopping rule with liver transaminases elevated more than 10 times the upper reference limit in week 8. However, the patient’s intrahepatic triglyceride content was only 0.8% when measured in week 9, and transaminases returned to normal within four weeks. Hepatic 1H-MRS was performed in all patients with elevated liver transaminases (>2 times upper reference limit); hepatic steatosis was detected in 12 of 14 patients in the mipomersen group compared to 1 of 1 placebo-treated patients. The median intrahepatic triglyceride content was 24.4% in the mipomersen group, ranging from 0.8% to 47.3%.

Conclusion

Mipomersen is an antisense apoB synthesis inhibitor that is currently in Phase III development for FH as a new treatment to lower apoB and LDL-cholesterol in patients at high risk of atherosclerotic CHD. Mipomersen is distributed mainly...
to the liver where it silences apoB mRNA, thereby reducing hepatic apoB-100 and giving rise to reductions in plasma total cholesterol, LDL-cholesterol, and apoB concentrations in a dose- and time-dependent manner. Unlike statins, mipomersen is not dependent on the LDL receptor for its mechanism of action.

Mipomersen has been shown to decrease apoB, LDL-cholesterol and Lp(a) in patients with heterozygous and homozygous FH on maximally tolerated lipid-lowering therapy. Furthermore, mipomersen has the potential to reduce the frequency of LDL apheresis. The short-term efficacy and safety of mipomersen has been established, however, injection site reactions are a common occurrence and concern exists regarding the long-term potential for hepatic steatosis with this ASO and more detailed safety evaluations on human liver function are required.

The requirement for injection of mipomersen could present a barrier to patient uptake of this therapy. Further studies are required to develop an alternative delivery mode that would make this form of ASO available to a wider spectrum of patients who require to be treated to lower target levels of LDL-cholesterol either because current therapy is inadequate or that they cannot tolerate statins.

In summary, mipomersen given alone or in combination with standard lipid lowering medications shows promise as an adjunct therapy in patients with homozygous or refractory heterozygous FH at high risk of atherosclerotic CHD, who are not at target or are intolerant of statins. The long-term efficacy and safety and cost-effectiveness of mipomersen need to be demonstrated.

Acknowledgment

JRB is supported by a Practitioner Fellowship from the Royal Perth Hospital Medical Research Foundation.

Disclosure

The authors report no conflicts of interest in this work.

References


